HKEX eyes more global biotechs to build IPO hub

Amid a structural shift towards Asia, Insilico Medicine's IPO in December was a significant moment for the exchange, while French biotech TheraVectys is understood to be considering a listing.

The trend of initial public offerings (IPOs) of foreign biotech firms on the Hong Kong Stock Exchange (HKEX), though nascent, has the potential to take the Asian financial hub to a higher level internationally.

¬ Haymarket Media Limited. All rights reserved.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media